lonidamine has been researched along with Bladder Cancer in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ambrogi, F; Ciottoli, GB; Giannotti, P | 1 |
| Coptcoat, M; Masters, JR; Popert, RJ; Zupi, G | 1 |
| Belmonte, P; Francini, M; Lo Re, G; Monfardini, S; Morassut, S; Tumolo, S; Veronesi, A | 1 |
1 trial(s) available for lonidamine and Bladder Cancer
| Article | Year |
|---|---|
Lonidamine plus adriamycin versus adriamycin alone in the adjuvant treatment of recurrent papillary carcinomas of the urinary bladder.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Papillary; Doxorubicin; Eye; Female; Heart; Humans; Indazoles; Male; Middle Aged; Pyrazoles; Urinary Bladder Neoplasms | 1984 |
2 other study(ies) available for lonidamine and Bladder Cancer
| Article | Year |
|---|---|
Relative cytotoxicities of adriamycin and epirubicin in combination with lonidamine against human bladder cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Doxorubicin; Drug Resistance, Multiple; Epirubicin; Humans; Indazoles; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 1995 |
Partial response to lonidamine of advanced bladder carcinoma: a case report.
Topics: Aged; Antineoplastic Agents; Carcinoma, Transitional Cell; Female; Humans; Indazoles; Pyrazoles; Urinary Bladder Neoplasms | 1990 |